MedTrace Logo

Efficacy of SGLT2 Inhibitors in Adults With Sepsis

NCT06473844 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-03-19

No results posted yet for this study

Summary

Goal of this clinical trial is to examine the safety and efficacy of SGLT2 inhibitors on the clinical outcomes in patients with sepsis. Main study outcomes are as follows:

(i) Primary objective is to examine the efficacy and safety of SGLT2 inhibitors on clinical outcomes in patients with sepsis.

(ii) Secondary objective is to examine the effect of SGLT2 inhibitors on inflammatory markers in patients with sepsis.

Conditions

Interventions

DRUG

Empagliflozin 10 MG

Empagliflozin 10mg once daily from recruitment to hospital discharge

DRUG

Placebo

Placebo single tablet once daily from recruitment to hospital discharge

Sponsors & Collaborators

  • Chinese University of Hong Kong

    collaborator OTHER

  • Hospital Authority, Hong Kong

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-05
Primary Completion
2027-02-28
Completion
2027-02-28

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06473844 on ClinicalTrials.gov